1 cancer, but confounding by drug use needs to
be followed up.
2 us strains, and development of the infection
was followed up.
3 syndrome or controls with related disorders
were followed up.
4 Among the 8844 survivors, 8128 (92%)
were followed up.
5 All patients
were followed up 1 year after cardiac arrest.
6 hundred thirty subjects, mean age 61 years,
were followed up:
38 with childhood asthma; 53 with chil
7 Twins
were followed up a median of 32 years between 1943 and 2
8 The same subjects
were followed up after 5 y to determine changes in gluco
9 the 2900 individuals (50.1%) at risk for AMD
were followed up after 6 years (mean [SD] age, 60.7 [8.2
10 (4.9%) died in the hospital and 1405 infants
were followed up after discharge.
11 A total of 21 patients
were followed up after treatment.
12 Patients
were followed-up after 14 +/- 4 months.
13 the 93 patients who underwent treatment, 82
were followed-up after transplantation (mean duration, 7
14 ich was followed up in 1989, 1995, and 2001,
was followed up again in 2014 when at age 60 to 65 years
15 ntification to determine whether the patient
was followed up and, if so, whether treatment was initia
16 Participants
were followed up and annual hospital costs and admission
17 Managers and their employees
were followed up and reassessed at 6 months after random
18 Patients
were followed up and reassessed at weeks 6, 12, 36, 52,
19 A total of 892 contacts
were followed up,
and blood specimens were collected fro
20 Five patients continued to
be followed up as of March 2017.
21 atients diagnosed as having glaucoma who had
been followed up at the Visual Performance Laboratory, U
22 Patients
were followed up at 1 month, 3 months, 6 months, and 12
23 secutively recruited patients with psoriasis
were followed up at 1 year.
24 fant pairs; of these, 13557 children (79.5%)
were followed up at 16 years of age between September 20
25 of 26,184 pregnant women and their children
were followed up at 2-year intervals until the age of 6
26 Participants were assessed at baseline and
were followed up at 3, 6, and 9 months.
27 ed, longitudinal HealthNuts Study (n = 5276)
were followed up at 4 years of age with repeat oral food
28 Jan 1, 2013, and March 31, 2013, all of whom
were followed up at 4 years of age.
29 Patients
were followed up at 6 months and 1 year after randomisat
30 opulation of all randomised participants who
were followed up at 6 months.
31 y 2007 and June 2012 in Victoria, Australia,
were followed up at 6, 12, and 24 months after injury to
32 ster dose; 67 of 75 study vaccine recipients
were followed up at 8 months.
33 ngletons in a population-based birth cohort)
were followed up at age six and half years.
34 Infants
were followed up at ages 6 (n = 2956) and 12 (n = 2872)
35 These subjects
were followed up at least for 12 months.
36 -onset ADAD and 12 noncarrier family members
were followed up at the Knight Alzheimer Disease Researc
37 This group of patients
was followed up beginning on their 15th birthday until t
38 Myocardial contractility
was followed up by cardiac magnetic resonance (CMR) and
39 Disc quality
was followed up by magnetic resonance imaging.
40 Respiratory outcomes
were followed up by questionnaires until age 5, when for
41 uritis (49 females, mean age 33.5 years) and
were followed up clinically 2 and 5 years later.
42 s of current asthma was ultimately ruled out
were followed up clinically with repeated bronchial chal
43 Patients with celiac disease should
be followed up closely for dietary adherence, nutritiona
44 atric eyes with noninfectious uveitis should
be followed up closely for IOP elevation, especially whe
45 Such patients should
be followed up closely to monitor the treatment response
46 Such patients should
be followed up closely to prevent fast lung function dec
47 h up to 3 individuals who continued PI, were
being followed up during the calendar period of the swit
48 ed doses or a single dose of albendazole and
were followed up during 13 months to assess the incidenc
49 After DAT-SPECT, patients
were followed up during 5.7 +/- 2.2 (range, 2.6-9.9) yea
50 ed influenza vaccine (IIV3) during pregnancy
were followed up during the first 6 months of life for p
51 ndividuals born in Denmark from 1955 to 2012
were followed up during the study period (total follow-u
52 Two hundred ten patients
were followed up every 3 months, with a mean follow-up o
53 Participants
were followed up every 6 months, and data at the baselin
54 rom the English Longitudinal Study of Ageing
were followed-up every two years until they reported a d
55 atients in the single-drug doxorubicin group
were followed up expectantly whereas patients with stabl
56 These patients should
be followed up for a prolonged time to determine whether
57 All the patients will
be followed-up for a maximum of 6 months.
58 o had undergone one of the interventions and
been followed up for at least 1 year.
59 She was
being followed up for mild hypercalcemia (calcium level,
60 All patients not on active study therapy are
being followed up for survival.
61 ABPA status
was followed up for 1 year.
62 d 185 deaths and the control treatment group
was followed up for a mean 128 days and had 87 deaths.
63 The long-acting opioid group
was followed up for a mean 176 days and had 185 deaths a
64 A cohort of 770 pCIS patients
was followed up for at least 10 years.
65 The patient
was followed up for clinical and radiologic regression o
66 In addition, the cohort
was followed-up for the onset of clinical Parkinson's di
67 mab (n = 5007) or not (n = 2829) at baseline
were followed up for </=5 years.
68 Patients with a graft rejection episode
were followed up for 1 additional year.
69 Clinical outcomes
were followed up for 1 year and included evaluation of p
70 meningoradiculitis (Bannwarth syndrome) who
were followed up for 1 year at a single center.
71 on the basis of PA:A ratio (>1 or </=1) and
were followed up for 1 year in the derivation cohort and
72 week socioeconomic intervention, of whom 231
were followed up for 1 year.
73 at a single center between 1986 and 2014 and
were followed up for 1 year.
74 unctional disability and all-cause mortality
were followed up for 1,374 d (follow-up rate = 96.1%).
75 (fMRI) before making a quit attempt and then
were followed up for 10 weeks after their quit date.
76 Patients
were followed up for 10 years.
77 Patients
were followed up for 12 months after stricture resolutio
78 Participants
were followed up for 12 months with masked outcome asses
79 ition) subthreshold depression; participants
were followed up for 12 months.
80 Patients
were followed up for 12 months.
81 All patients
were followed up for 12 months.
82 Participants
were followed up for 12 months.
83 Participants
were followed up for 12.5 years, with 57 incident CHD ev
84 Patients
were followed up for 14 months.
85 range, 44-100 years; 56% female; 77% white)
were followed up for 14.0 years (median).
86 Two hundred fifty-six patients
were followed up for 16.3+/-3.8 months.
87 ins, Zn+MVs, or a placebo at 6 wk of age and
were followed up for 18 mo with monthly growth measureme
88 dents who were 15 years or older (N = 77774)
were followed up for 2 years (2013-2014 to 2015-2016).
89 Patients
were followed up for 2 years (up to April 2013) and 215
90 -seeing eye, at either of 2 dose levels, and
were followed up for 2 years after treatment.
91 Subjects
were followed up for 2 years from intervention.
92 Foundation Trust in London, UK, 245 patients
were followed up for 2 years from the onset of first-epi
93 from 2000 to 2011 (n = 1375) in our hospital
were followed up for 2 years, evaluating 3 time periods.
94 Patients
were followed up for 2 years.
95 0 mg/mL) injections given 2 weeks apart, and
were followed up for 2 years.
96 nger than 6 years with a first or second UTI
were followed up for 2 years.
97 All participants
were followed up for 2 years.
98 nt of Aortic Transcatheter Valve 2 Trial and
were followed up for 2 years.
99 e studies included 1 005 791 individuals who
were followed up for 2-18.1 years, during which 84 609 (
100 Patients
were followed up for 2.3+/-1.1 years.
101 Participants
were followed up for 21 days to determine pneumococcal c
102 n consisted of 5205 individuals with HIV who
were followed up for 24 031 person-years.
103 MECs patients
were followed up for 25-69 months after surgery, present
104 andard care, versus standard care alone, and
were followed up for 28 days.
105 tamivir) twice a day for 5-10 days; patients
were followed up for 28 days.
106 y for 5 days, given orally, and participants
were followed up for 28 days.
107 ging Municipal Employees (FLAME) in 1981 and
were followed up for 28 years.
108 Participants
were followed up for 3 and 10 years for falls leading to
109 All patients
were followed up for 3 months before transplantation and
110 Patients
were followed up for 3 years.
111 A total of 277 eyes of 188 participants
were followed up for 3.7 +/- 2.1 years.
112 consecutive ambulatory patients with HF who
were followed up for 4.1 years.
113 from May 30, 2011, to December 11, 2014, and
were followed up for 42 days after treatment.
114 Patients
were followed up for 42 days during the years 2009-15.
115 SAPPHIRe) family study, and 759 participants
were followed up for 5 years.
116 A total of 136 eyes of 123 patients
were followed up for 57.7 +/- 16.2 months.
117 Participants
were followed up for 6 months.
118 y before the transplant surgery and patients
were followed up for 6 months.
119 Participants
were followed up for 6 years, with biannual visits inclu
120 Subjects
were followed up for 7.5 years.
121 Patients
were followed up for 8 weeks (all patients) and up to 76
122 adults and 194 children), and all vaccinees
were followed up for 84 days.
123 ated antiretroviral therapy in 2004-2005 and
were followed up for 9 years, we calculated patients' ti
124 Patients
were followed up for a mean (SD) of 26.7 (2.7) months (r
125 Patients with cataract surgery
were followed up for a mean of 11.4 quarters (standard d
126 ), whereas patients without cataract surgery
were followed up for a mean of 12.9 quarters (SD, 12.2 q
127 223 880 men and women
were followed up for a mean of 13 years (SD 6).
128 Glaucoma patients
were followed up for a mean of 3.90 years (range, 2.03-5
129 All women
were followed up for a mean of 38.8 months to analyze da
130 m February 7, 2005, to January 15, 2013, and
were followed up for a mean of 4.1 years through the stu
131 We recruited 2404 adult patients with FH who
were followed up for a mean of 5.5 years (SD, 3.2 years)
132 2%) of whom had also made a suicide attempt,
were followed up for a mean of 5.6 years.
133 ood Frequency Questionnaire in 1993-1997 and
were followed up for a median of 10 y.
134 Patients
were followed up for a median of 10.4 months (IQR 8.6-13
135 Individuals
were followed up for a median of 14.6 years.
136 Study participants
were followed up for a median of 17.4 years (range, 0.1-
137 Patients
were followed up for a median of 2.6 years (IQR 2.0-3.2)
138 601 children
were followed up for a median of 2.9 years (IQR 1.5-4.4)
139 Transplanted patients
were followed up for a median of 22 months by use of ser
140 These participants
were followed up for a median of 33 months (study start
141 ticipants chose to start open-label PrEP and
were followed up for a median of 335 days (IQR 0-364).
142 Thirty-five patients underwent LT and
were followed up for a median of 38 months.
143 Patients
were followed up for a median of 4.5 years.
144 Patients
were followed up for a median of 5.0 years (IQR 3.4-6.0)
145 Participants
were followed up for a median of 5.6 years (range 0.3-20
146 ange, 40.0-61.0 years; 1354 men [51.0%]) and
were followed up for a median of 5.6 years, 470 patients
147 iously hospitalized with S aureus bacteremia
were followed up for a median of 7.8 years (interquartil
148 iversity Hospital during 1992-2013 (n = 399)
were followed up for a median of 7.8 years.
149 s from debridement; patients without failure
were followed up for a median of 802 days.
150 ween May 21, 2005, and Dec 1, 2015, patients
were followed up for a median of 83 months (IQR 69-94 mo
151 Patients
were followed up for a minimum of 24 months.
152 Eighty-three patients
were followed up for a minimum of 3 years, with a local
153 Patients
were followed up for an additional 2 weeks.
154 ad preserved ejection fraction; and patients
were followed up for an average of 333+/-125 days.
155 , and had no previous cancer at recruitment,
were followed up for an average of 4.9 years from April
156 w-up started at age 1 year, and the children
were followed up for as long as 10.7 years (median, 5.5
157 cognitive impairment at first assessment who
were followed up for as long as 36 years (mean [SD], 12.
158 adolescents who visited the draft board and
were followed up for as much as 25.4 years from draft bo
159 with single-dose azithromycin (30 mg/kg) and
were followed up for assessment of clinical resolution.
160 All patients
were followed up for at least 1 year, or had a censoring
161 Patients
were followed up for at least 1 year.
162 Patients
were followed up for at least 12 months; median follow-u
163 Patients
were followed up for at least 2 visits after enrollment.
164 d final analysis occurred after all patients
were followed up for at least 21 months.
165 Patients
were followed up for at least 6 months and for up to 33
166 I posterior who received IVB monotherapy and
were followed up for at least 65 weeks adjusted age (AA)
167 Participants
were followed up for clinical events through central reg
168 acy included two large regional cohorts that
were followed up for dengue infection.
169 Children
were followed up for diagnoses of ASD (International Cla
170 in Denmark and Sweden between 1987 and 2012
were followed up for diagnosis of thromboembolism and ar
171 Cancer survivors and comparisons
were followed up for hospitalizations in the Danish Pati
172 Participants
were followed up for incident cancer diagnoses, which we
173 nts a mean (SD) of 5.9 (0.6) years apart and
were followed up for incident dementia throughout the st
174 All patients
were followed up for major adverse cardiac events (MACE)
175 Of the 1585 patients, 1175
were followed up for more than 1 year after PVI.
176 Failure Registry (SwedeHF) from 2003 to 2011
were followed up for mortality predictors and longevity.
177 echocardiography, and 6-minute walk test and
were followed up for mortality until the end of December
178 They
were followed up for over 48 months for function of the
179 A total of 368 SNPs
were followed up for replication.
180 The women
were followed up for respiratory illness from midpregnan
181 3 in Europe (Finland, Germany, and Sweden),
were followed up for T1DM-related autoantibodies.
182 108 participants with pre-DM
were followed up for ten years and divided into 3 groups
183 Patients
were followed up for the composite end point of death, u
184 Patients
were followed up for the primary outcome of 28-day morta
185 All participants
were followed up for up to 1 year.
186 Patients
were followed up for up to 1 year.
187 types for celiac disease and type 1 diabetes
were followed up for up to 20 years for development of t
188 of the 12-month study, a subset of patients
were followed up for up to 24 months.
189 Participants
were followed up for up to 5 years after their last annu
190 All participants
were followed up for up to 5.3 years (median, 3.2 years)
191 ral regurgitation had baseline CMR scans and
were followed up for up to 8 years (mean, 2.5+/-1.9 year
192 s with symptomatic small vessel disease, who
were followed-up for >/=1 years.
193 kg agalsidase-alpha (switch group, n=37) and
were followed-up for 2 years.
194 Total 323175 adults
were followed-up for 96 (60-120) (median [5-95%]) months
195 Participants
were followed-up for CVD mortality after linkage to nati
196 All participants
were followed-up for medically certified cardiac events
197 NPs are new for serum metabolite levels, and
were followed-up for replication in an independent sampl
198 nformation about childhood bullying behavior
was followed up from 8 to 29 years of age.
199 ween January 1, 1979, and December 31, 2001,
was followed up from age 6 years to December 31, 2009 (N
200 Three hundred thirty-seven adult patients
were followed up from 1 to 36 months after kidney transp
201 viduals born in Sweden from 1987 to 2012 who
were followed up from 1 year of age to December 31, 2013
202 en from Health Professionals Follow-Up Study
were followed up from 1984 to 2012 and from 1986 to 2010
203 ntal information from national registers who
were followed up from birth throughout 2014.
204 members of the New Zealand Dunedin Study who
were followed up from birth until ages 18 and 38 years,
205 members of the New Zealand Dunedin Study who
were followed up from birth until ages 18 and 38 years,
206 rdiovascular Risk in YFS (Young Finns Study)
were followed up from childhood (age 3-18 years) to adul
207 A total of 1016 women
were followed up from gestational week 17 to delivery.
208 All participants
were followed up from inclusion in the studies to Novemb
209 They
were followed up from January 1, 1973, until December 31
210 ed 15 to 34 years who were living in Denmark
were followed up from January 1, 2000, to December 2013,
211 3 million people born between 1955 and 2006
were followed up from January 1, 2002, through December
212 Medicare patients
were followed up from procedure date until death, stroke
213 All patients without prior AMD
were followed up from the date of diagnosis (or correspo
214 Subsequently, 16 sequence variants
are followed up in a diverticular disease sample from De
215 l as low-risk patients who could potentially
be followed up in primary care.
216 cruited in 1964 at age 10 to 15 years, which
was followed up in 1989, 1995, and 2001, was followed up
217 e participants (age, >/=40 years; 2006-2008)
were followed up in 2011 through 2013, and 1901 of 3280
218 al of 82 variants with p-value </=1 x 10(-5)
were followed up in 373 African Americans.
219 These findings
were followed up in a specifically selected cohort, in w
220 Promising association signals
were followed up in additional data sets (of 14,545 or 7
221 Participants
were followed up in hospital wards and at 3 and 6 months
222 Individuals
were followed up in the nationwide Psychiatric Central R
223 115 of these cases
were followed up in the survey.
224 The three associated variants
were followed-up in the Chinese cohort; one SNP rs170183
225 of 435 patients without dementia at 6 months
were followed up longitudinally (median follow-up, 47.4
226 e LA function in 308 patients with HFpEF who
were followed up longitudinally for adverse outcomes.
227 rithm 30-2 Standard or Fast), and 36 of them
were followed up (
median interval, 10 months after basel
228 orally once daily for 3 months, and patients
were followed up monthly for 4 months.
229 mycophenolate mofetil, 1 g twice daily, and
were followed up monthly for 6 months.
230 VD, which suggests that these persons should
be followed up more closely to prevent CVD.
231 was 97.9 (85.8) months; 83 patients (91.2%)
were followed up,
of whom 37 (44.58%) experienced a recu
232 re pre-emptive antiviral therapy, but should
be followed up on a monthly basis for alanine aminotrans
233 Patients
were followed up on a 6-monthly basis for reassessment a
234 Patients
were followed up on days 1, 7, and 28 and then every 2 m
235 Subjects
were followed up over a maximum of 113 d.
236 A total of 7542 recipients
were followed up over a median follow-up time of 5.3 yea
237 Sept 30, 2012, 2 010 398 cohort participants
were followed up over a median of 8.52 years (IQR 8.05-8
238 ond extensively drug-resistant tuberculosis,
were followed up over a period of 6 years.
239 the skin in a cohort of 217 participants who
were followed up over the first 2 rounds of biannual tre
240 Participants
were followed up prospectively for SCC development.
241 n whom active tuberculosis developed and who
were followed up prospectively.
242 3 of 22 focused on how often patients should
be followed up (
re-examination) and treatment effectiven
243 ssed by electroencephalography; 202 patients
were followed up regarding the occurrence of overt HE an
244 ween January 1, 2004, and December 31, 2011,
was followed up through December 31, 2012, to study the
245 The women
were followed up through 2009.
246 Participants
were followed up through 2012 with a 99% successful foll
247 Participants
were followed up through December 31, 2010.
248 m January 1, 1973, to December 31, 1996, who
were followed up through December 31, 2013.
249 January 1, 2008, and December 31, 2012, and
were followed up through December 31, 2013.
250 1, 2010, and no prior HF; study participants
were followed up through March 31, 2013.
251 en June 19, 2003, and September 3, 2008, and
were followed up through March 31, 2013.
252 Patients
were followed up through to Dec 31, 2014.We assessed the
253 Participants
were followed-up through 2012 to assess incident frailty
254 se who develop postoperative delirium should
be followed up to enable early detection of dementia sym
255 the basis of data from 213 patients who had
been followed up to autopsy and met inclusion criteria o
256 They
were followed up to 18 to 19 years of age, with 81.3% re
257 049 newborns were enrolled, and 9336 (77.5%)
were followed up to 2 years of age.
258 Remaining mice
were followed up to 22 months.
259 Patients
were followed up to 3 years.
260 itudinal Study and Normative Aging Study who
were followed up to 33 y from 1981 to 2013.
261 In addition, 346 eligible children
were followed up to assess reactions to subsequent use o
262 %) newborn babies in the dry cord care group
were followed up to day 28 or death.
263 Patients
were followed up to days 28-35 after first dose.
264 t between Jan 1, 2007, and Dec 31, 2013, and
were followed up to Dec 31, 2014 (end of study).
265 ed between September and December, 2016, who
were followed up to detect whether they developed cutane
266 over the stroke-affected gastrocnemius) and
were followed up to poststroke d 14.
267 lder who were cognitively normal at baseline
were followed up to the outcome of incident MCI.
268 e, 74-82 years]; 50.4% [n = 973] female) who
were followed up to the outcome of incident MCI.
269 rth American Prodrome Longitudinal Study who
were followed up to the time of conversion to psychosis
270 clefts and 1 413 819 unaffected individuals,
was followed up until December 31, 2010, using compulsor
271 The cohort
was followed up until September 30, 2012.
272 , to women with a history of CS (n = 40,145)
were followed up until 31 January 2015.
273 the quadrivalent meningococcal vaccine group
were followed up until age 6 months.
274 Patients
were followed up until August 2015 (complete follow-up t
275 Patients
were followed up until day 30.
276 All patients
were followed up until day 42.
277 Patients
were followed up until death or were censored on Decembe
278 tal of 309 patients (309 eyes) with glaucoma
were followed up until death; 203 patients (65.7%) had p
279 All people living in Spain on Nov 1, 2001,
were followed up until Dec 31, 2011.
280 ish registers, cases, siblings, and controls
were followed up until December 31, 2011.
281 in 1999 with an acute head trauma (n = 737)
were followed up until February 2014 and compared with a
282 patients, 1,211 with chronic kidney disease,
were followed up until hospital death or discharge.
283 Patients
were followed up until hospital discharge or death.
284 Subsequently, participants
were followed up until January 1, 2015, for the onset of
285 Children
were followed up until March 31, 2014.
286 ance between January 2012 and April 2015 and
were followed up until November 2015.
287 The imaging characteristics
were followed up until the occurrence of PML-IRIS.
288 Participants
were followed up until their death or November 24, 2014.
289 A total of 418,057 adults
were followed-up using a nationwide prospective cohort s
290 n, including 24-h respiratory recording, and
were followed-up using cardiac mortality as an endpoint.
291 lywise error cluster-level corrected p<0.05)
were followed up via Tukey-corrected pairwise comparison
292 gible patients (308 patients [96.9%] of whom
were followed up)
were older and had more advanced disea
293 ory-confirmed cases of meningococcal disease
are followed up with PHE local health protection teams,
294 This is a preliminary report that would
be followed up with information on medium and long term
295 December 2002 and December 2011 and who had
been followed up with imaging and clinical evaluation fo
296 Patients
were followed up with contrast-enhanced CT every 2-4 mon
297 Nodules without pathologic confirmation
were followed up with MR imaging every 6 months.
298 Children
were followed up with telephone calls and an in-person v
299 16,908 (84%) participants
were followed up with the 16 week questionnaire (8241 in
300 icant differences in the ROI-to-ROI analysis
were followed up with voxelwise seed-based analyses to f